Stock Events

Stock Events

IN8bio 

$0.9655
35
-$0.08-8.05%Monday 20:00
-$0.03-3%Monday 22:40After hours

Statistics

Day High
0.9634
Day Low
0.9568
52W High
2.73
52W Low
0.87
Volume
830
Avg. Volume
-
Mkt Cap
9.52M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.1
-1.42
-0.75
-0.07
Expected EPS
-0.336667
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-19.44MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INAB. It's not an investment recommendation.
MicroAlgo
5
MLGO
Global X NASDAQ 100 Covered Call
4
QYLD
Apple
3
AAPL
Realty Income
3
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences is a biopharmaceutical company that competes with IN8bio in the development of cancer therapies, including cell therapies.
Novartis
NVS
Mkt Cap268B
Novartis is a global healthcare company that competes in the oncology sector, particularly in the development of innovative cancer treatments similar to IN8bio's focus.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb is involved in the discovery, development, and delivery of cancer treatments, competing directly with IN8bio in the oncology space.
Allogene Therapeutics
ALLO
Mkt Cap518.24M
Allogene Therapeutics is focused on the development of allogeneic CAR T therapies for cancer, competing in the same space as IN8bio.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is engaged in gene editing and cell therapy, including for cancer, which puts it in competition with IN8bio's cell therapy approach.
Pfizer
PFE
Mkt Cap158.45B
Pfizer is a large pharmaceutical company with a broad oncology portfolio, competing across various aspects of cancer treatment, including areas targeted by IN8bio.

About

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Show More
CEO
William T.
Employees
18
Country
United States
ISIN
US45674E2081
WKN
000A4197Y

Listings

F
DE
6JH0.F
MU
DE
6JH.MU
STU
DE
6JH0.STU
MU
DE
6JH0.MU

0 Comments

Share your thoughts

FAQs

What is IN8bio stock price today?▼
The current price of INAB is $0.97 USD — it has decreased by -8.05% in the past 24 hours. Watch IN8bio stock price performance more closely on the chart.
What is IN8bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange IN8bio stocks are traded under the ticker INAB.
Is IN8bio stock price growing?▼
INAB stock has fallen by -15.31% compared to the previous week, the month change is a -19.54% fall, over the last year IN8bio has showed a -54.02% decrease.
What is IN8bio market cap?▼
Today IN8bio has the market capitalization of 9.52M
When is the next IN8bio earnings date?▼
IN8bio is going to release the next earnings report on November 5, 2026.
What were IN8bio earnings last quarter?▼
INAB earnings for the last quarter are -0.25 USD per share, whereas the estimation was -0.34 USD resulting in a +27.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is IN8bio revenue for the last year?▼
IN8bio revenue for the last year amounts to 0 USD.
What is IN8bio net income for the last year?▼
INAB net income for the last year is -19.44M USD.
How many employees does IN8bio have?▼
As of October 27, 2026, the company has 18 employees.
In which sector is IN8bio located?▼
IN8bio operates in the Health & Wellness sector.
When did IN8bio complete a stock split?▼
The last stock split for IN8bio was on June 6, 2025 with a ratio of 1:30.
Where is IN8bio headquartered?▼
IN8bio is headquartered in NEW YORK, United States.